110 related articles for article (PubMed ID: 8558797)
1. [Phase 3 multicenter clinical study of 111In-DTPA-D-octreotide (MP-1727) in patients with gastrointestinal hormone producing tumors].
Yamamoto K; Ishii Y; Furudate M; Ito K; Tsukamoto E; Kanamaru R; Endo K; Hirano T; Tanaka K; Ogino Y
Kaku Igaku; 1995 Nov; 32(11):1269-80. PubMed ID: 8558797
[TBL] [Abstract][Full Text] [Related]
2. Somatostatin-receptor scintigraphy in the management of gastroenteropancreatic tumors.
Krausz Y; Bar-Ziv J; de Jong RB; Ish-Shalom S; Chisin R; Shibley N; Glaser B
Am J Gastroenterol; 1998 Jan; 93(1):66-70. PubMed ID: 9448177
[TBL] [Abstract][Full Text] [Related]
3. Use of an isotopic somatostatin receptor probe to image gut endocrine tumors.
Modlin IM; Cornelius E; Lawton GP
Arch Surg; 1995 Apr; 130(4):367-73; discussion 373-4. PubMed ID: 7710334
[TBL] [Abstract][Full Text] [Related]
4. Receptor scintigraphy with 111In-pentetreotide for endocrine gastroenteropancreatic tumors.
Joseph K; Stapp J; Reinecke J; Skamel HJ; Höffken H; Neuhaus C; Lenze H; Trautmann ME; Arnold R
Horm Metab Res Suppl; 1993; 27():28-35. PubMed ID: 8330869
[TBL] [Abstract][Full Text] [Related]
5. [111In-pentetreotide in the study of tumors expressing somatostatin receptors].
Mateos Fernández J; Pons Pons F; Fuster Pelfort D; Vidal-Sicart S; Lomeña Caballero F; Herranz García-Romero R
Rev Esp Med Nucl; 1999 Oct; 18(5):325-30. PubMed ID: 10562660
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor scintigraphy in carcinoids, gastrinomas and Cushing's syndrome.
Krenning EP; Kwekkeboom DJ; Oei HY; de Jong RJ; Dop FJ; de Herder WW; Reubi JC; Lamberts SW
Digestion; 1994; 55 Suppl 3():54-9. PubMed ID: 7698538
[TBL] [Abstract][Full Text] [Related]
7. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
[TBL] [Abstract][Full Text] [Related]
8. Iodine-123-Tyr-3-octreotide uptake in pancreatic endocrine tumors and in carcinoids in relation to hormonal inhibition by octreotide.
Nocaudie-Calzada M; Huglo D; Deveaux M; Carnaille B; Proye C; Marchandise X
J Nucl Med; 1994 Jan; 35(1):57-62. PubMed ID: 8271061
[TBL] [Abstract][Full Text] [Related]
9. Internalization of indium-111 into human neuroendocrine tumor cells after incubation with indium-111-DTPA-D-Phe1-octreotide.
Andersson P; Forssell-Aronsson E; Johanson V; Wängberg B; Nilsson O; Fjälling M; Ahlman H
J Nucl Med; 1996 Dec; 37(12):2002-6. PubMed ID: 8970523
[TBL] [Abstract][Full Text] [Related]
10. [Somatostatin receptor scintigraphy in preoperative diagnosis of the site of endocrine gastrointestinal tumors].
Weinel RJ; Kisker O; Joseph K; Welcke U; Zaraca F; Rothmund M
Chirurg; 1994 Oct; 65(10):849-55. PubMed ID: 7821043
[TBL] [Abstract][Full Text] [Related]
11. The value of somatostatin-receptor scintigraphy in newly diagnosed endocrine gastroenteropancreatic tumors.
Kisker O; Bartsch D; Weinel RJ; Joseph K; Welcke UH; Zaraca F; Rothmund M
J Am Coll Surg; 1997 May; 184(5):487-92. PubMed ID: 9145069
[TBL] [Abstract][Full Text] [Related]
12. Current imaging and possible therapeutic management of glucagonoma tumors: a case report.
Johnson DS; Coel MN; Bornemann M
Clin Nucl Med; 2000 Feb; 25(2):120-2. PubMed ID: 10656647
[TBL] [Abstract][Full Text] [Related]
13. Localization of metastatic gastroenteropancreatic tumours by somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-octreotide.
Hammond PJ; Arka A; Peters AM; Bloom SR; Gilbey SG
Q J Med; 1994 Feb; 87(2):83-8. PubMed ID: 8153292
[TBL] [Abstract][Full Text] [Related]
14. [Somatostatin receptor scintigraphy in medullary thyroid carcinomas, GEP and carcinoid tumors].
Eising EG; Farahati J; Bier D; Knust EJ; Reiners C
Nuklearmedizin; 1995 Feb; 34(1):1-7. PubMed ID: 7724358
[TBL] [Abstract][Full Text] [Related]
15. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours.
Gotthardt M; Béhé MP; Grass J; Bauhofer A; Rinke A; Schipper ML; Kalinowski M; Arnold R; Oyen WJ; Behr TM
Endocr Relat Cancer; 2006 Dec; 13(4):1203-11. PubMed ID: 17158765
[TBL] [Abstract][Full Text] [Related]
16. Gastroenteropancreatic tumor imaging with somatostatin receptor scintigraphy.
Wiedenmann B; Bäder HM; Scherubl H; Fett U; Zimmer T; Hamm B; Koppenhagen K; Riecken EO
Semin Oncol; 1994 Oct; 21(5 Suppl 13):29-32. PubMed ID: 7992077
[No Abstract] [Full Text] [Related]
17. [A case of metastatic gastrinomas in the liver visualized by 111In-DTPA-D-Phe-octreotide (111In-pentetreotide)].
Tani A; Nakabeppu Y; Tsuchimochi S; Nakajo M; Yoshinaga T; Kiku T
Kaku Igaku; 1996 May; 33(5):545-9. PubMed ID: 8699623
[TBL] [Abstract][Full Text] [Related]
18. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors.
Anderson CJ; Dehdashti F; Cutler PD; Schwarz SW; Laforest R; Bass LA; Lewis JS; McCarthy DW
J Nucl Med; 2001 Feb; 42(2):213-21. PubMed ID: 11216519
[TBL] [Abstract][Full Text] [Related]
19. Indium-111 activity concentration in tissue samples after intravenous injection of indium-111-DTPA-D-Phe-1-octreotide.
Forssell-Aronsson E; Fjälling M; Nilsson O; Tisell LE; Wängberg B; Ahlman H
J Nucl Med; 1995 Jan; 36(1):7-12. PubMed ID: 7799086
[TBL] [Abstract][Full Text] [Related]
20. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.
Lamberts SW; Hofland LJ; van Koetsveld PM; Reubi JC; Bruining HA; Bakker WH; Krenning EP
J Clin Endocrinol Metab; 1990 Sep; 71(3):566-74. PubMed ID: 2168430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
